



November 01, 2011 10:31 AM Eastern Daylight Time

AxoGen Announces the Launch of Its Patient Website, AboutNerve.com

ALACHUA, Fla.--(BUSINESS WIRE)--AxoGen today announced the launch of a new patient website at www.aboutnerve.com. The site provides a resource for patients and caregivers dealing with peripheral nerve injuries. Visitors can access information on types of peripheral nerve injuries, how these injuries can be diagnosed and the potential treatment options available.

Karen Zaderej, CEO of AxoGen, Inc., stated, "Peripheral nerves play an important role in our daily activities. Yet we find that the peripheral nerves and their impact to quality of life and the options for treatment are often poorly understood. This new website provides an important educational resource for patients and caregivers who need information about peripheral nerves."

"Helping patients has always been the driving force of our company. This website seeks to provide patients with the tools they need to understand their condition and make informed decisions"

The site includes an interactive injury map where visitors can learn more about specific peripheral nerve injuries and their causes and symptoms. A glossary of terms related to nerve injury and repair is available to further patient understanding and facilitate communication with their healthcare providers.

"Helping patients has always been the driving force of our company. This website seeks to provide patients with the tools they need to understand their condition and make informed decisions," Zaderej added.

About AxoGen, Inc.

AxoGen, Inc. ("AxoGen") is a regenerative medicine company focused on the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes the Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). AxoGen's portfolio also includes the AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and the AxoGuard® Nerve Protector that protects nerves during the body's healing process after surgery. AxoGen is bringing the science of nerve repair to life with over 6,000 surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen (formerly known as LecTec Corporation) is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen's principal executive office and operations are located in Alachua, FL. AxoGen's common stock currently trades on the Over-the-Counter Bulletin Board under the symbol "AXGN."

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "may", "should", variations of such words and similar expressions are intended to identify such

forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Visit AxoGen at: www.axogeninc.com

Follow @AxoGen on Twitter!

Contacts

AxoGen, Inc.

Monica L. Tarver, +1-386-462-6834

mtarver@axogeninc.com

or

The Cockrell Group,

Rich Cockrell, +1-404-942-3369

President

Investorrelations@thecockrellgroup.com

@COCKRELLGROUP

